In order to provide a botulinum toxin preparation having no side effects at a non-administration site, a molecular weight of 150 kDa derived from a botulinum bacterium that does not produce HA protein, and does not exhibit side effects associated with axonal transport at sites other than the administration site A pharmaceutical composition containing a neurotoxin as a main component is used. Since the botulinum neurotoxin is not transported to the non-administration site via the nerve axon as compared with the A1-type botulinum-derived neurotoxin, the botulinum neurotoxin can be administered in a large amount from 15 U to 25 U or less per kg of body weight.非投与部位での副作用のないボツリヌス毒素製剤を提供するために、投与部位以外の部位において軸索輸送に伴う副作用を示さないことを特徴とするＨＡ蛋白質非産生性のボツリヌス菌に由来する分子量１５０ｋＤａの神経毒素を主成分として含有する医薬組成物を用いる。上記ボツリヌス神経毒素は、Ａ１型ボツリヌス菌由来神経毒素と比較して、神経軸索を介して非投与部位へ輸送されないため、体重１ｋｇあたり１５Ｕより多く２５Ｕ以下まで大量投与可能となる。
